secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0001104659-21-142578
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports record FY2021 revenue $132.3M (+47% YoY), guides FY2022 rev $183M-$193M
--------------------------------------------------------------------------------

- FY2021 revenue $132.3M, up 47% from $90.1M; net loss $152.1M vs $139.9M.
- Q4 revenue $38.0M (+17% YoY); net loss $41.2M ($0.84/share) vs $24.3M ($0.54/share).
- FY2022 revenue guidance $183M-$193M, representing ~42% growth at midpoint.
- Cash and investments $477.9M at Sept 30, 2021.
- Announced acquisition of Abveris to add in vivo antibody discovery capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000110465921142578/0001104659-21-142578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000110465921142578/tm2133571d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-142578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer